CSL shares increased by 6% due to strong demand for its CSL Behring division.

2 min read | February 11, 2025 10:30 AM AEDT | By Team Kalkine Media

CSL shares increased by 6% due to strong demand for its CSL Behring division. — Image source: Shutterstock

CSL Behring’s Contribution to Growth

The CSL Behring segment was the primary driver of revenue expansion, with a 10% increase in its segment revenue. Immunoglobulin therapies, widely used for autoimmune conditions, saw 15% sales growth, reaching US$3.17 billion. The increasing adoption of these treatments across various markets significantly contributed to the company’s revenue gains.

Challenges in Other Segments

While CSL Behring delivered strong results, the CSL Seqirus segment, focused on influenza vaccines, faced headwinds due to lower immunization rates in the U.S. However, CSL Vifor witnessed solid growth in its nephrology portfolio, benefiting from rising iron demand and expansion in European markets.

Strategic Focus and Financial Outlook

CEO and Managing Director Dr. Paul McKenzie outlined plans to enhance gross margins by optimizing costs and improving operational efficiency. CSL Ltd also announced an interim dividend of US$1.30 per share (AU$2.08 per share), reflecting a 16% increase.

With continuous advancements in medical science and strategic expansion, CSL Ltd remains well-positioned in the dynamic biotechnology landscape. The coming quarters will be key in determining the long-term impact of these initiatives.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.